Genetic Susceptibility Toward Nausea and Vomiting in Surgical Patients

Yvonne Gloor, Christoph Czarnetzki, François Curtin, Béatrice Gil-Wey, Martin R. Tramèr and Jules A. Desmeules on behalf of the DexPONV study consortium

Front. Genet., 31 January 2022 Sec. Pharmacogenetics and Pharmacogenomics | https://doi.org/10.3389/fgene.2021.816908

Abstract

Postoperative nausea and vomiting (PONV) are frequently occurring adverse effects following surgical procedures. Despite predictive risk scores and a pallet of prophylactic antiemetic treatments, it is still estimated to affect around 30% of the patients, reducing their well-being and increasing the burden of post-operative care. The aim of the current study was to characterize selected genetic risk factors of PONV to improve the identification of at risk patients. We genotyped 601 patients followed during the first 24 h after surgery for PONV symptoms in the absence of any antiemetic prophylaxis. These patients were recruited in the frame of a randomized, placebo controlled clinical study aiming to test the efficacy of dexamethasone as a treatment of established PONV. We examined the impact of selected single nucleotide polymorphisms (SNPs) located around 13 different genes and the predicted activity of 6 liver drug metabolizing enzymes from the cytochromes P450 family (CYP) on the occurrence and recurrence of PONV. Our genetic study confirms the importance of genetic variations in the type 3B serotonin receptor in the occurrence of PONV. Our modelling shows that integration of rs3782025 genotype in preoperative risk assessments may help improve the targeting of antiemetic prophylaxis towards patients at risk of PONV.

Clinicaltrials.gov identifier: NCT01975727